The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Phase II neoadjuvant trial with carboplatin and eribulin mesylate in patients with triple-negative breast cancer.
Sara E. Barnato
No relevant relationships to disclose
Jacqueline Sara Jeruss
No relevant relationships to disclose
Kevin P. Bethke
No relevant relationships to disclose
Nora M. Hansen
No relevant relationships to disclose
Seema Ahsan Khan
No relevant relationships to disclose
Jamie H. Von Roenn
Consultant or Advisory Role - AstraZeneca
Steven T. Rosen
No relevant relationships to disclose
William John Gradishar
No relevant relationships to disclose
Kalliopi P. Siziopikou
No relevant relationships to disclose
Caitlin Meservey
No relevant relationships to disclose
Virginia G. Kaklamani
No relevant relationships to disclose